| 摘要 |
A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6.beta., 7.beta.; 15.beta.; 16.beta.-dimethylene-3-oxo-17.alpha.-preg-4-ene-21, 17-carbolacton e (drospirenone, DRSP) in sufficient amounts to protect the endometrium from t he adverse effects of estrogen is useful for, amongst others, treating peri- menopausal, menopausal and post-menopausal women. This composition may be us ed for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous , sequential or interrupted administration, or combinations thereof, of DRSP a nd estrogen, each optionally in micronized form.
|
